Search Results - "Guenzel, C.A."

1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma by Schadendorf, D., Dummer, R., Flaherty, K.T., Robert, C., Arance Fernandez, A.M., de Groot, J.W., Garbe, C., Gogas, H., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Guenzel, C.A., Polli, A., Thakur, M., di Pietro, A., Ascierto, P.A.

Get full text

273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial by Hurvitz, S.A., Rugo, H.S., Ettl, J., Martin, M., Roche, H., Lee, K-H., Goodwin, A., Usari, T., Lanzalone, S., Guenzel, C.A., Blum, J., Litton, J.K.

Get full text

272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC) by Martin, M., Rugo, H.S., Hurvitz, S.A., Ettl, J., Roche, H., Lee, K-H., Goodwin, A., Usari, T., Lanzalone, S., Guenzel, C.A., Blum, J., Litton, J.K.

Get full text

602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma by Haydon, A.M., Schadendorf, D., Dummer, R., Flaherty, K.T., Robert, C., Arance Fernandez, A.M., de Groot, J.W., Garbe, C., Gogas, H., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Guenzel, C.A., Polli, A., Thakur, M., Di Pietro, A., Ascierto, P.A.

Get full text